Abstract
Encorafenib (Braftovi®) is an oral small molecule BRAF inhibitor used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, who have received prior systemic therapy. In a clinical trial in adults with BRAF V600E-mutated mCRC who had disease progression after one or two previous regimens (BEACON CRC), encorafenib plus cetuximab was associated with a significantly longer median overall survival (OS), a higher objective response rate (ORR) and longer median progression-free survival (PFS), compared with standard therapy. Encorafenib plus cetuximab had a manageable tolerability profile in BEACON CRC. Current evidence suggests that encorafenib plus cetuximab combination therapy is an important targeted regimen for patients with mCRC and a BRAF V600E mutation who have received prior therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422.
Curigliano G, Sessa C, Buske C, et al. ESMO pocket guidelines: lower gastrointestinal cancer. 2020. http://www.esmo.org. Accessed 22 Feb 2021.
Safaee Ardekani G, Jafarnejad SM, Tan L, et al. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS ONE. 2012;7(10):
European Medicines Agency. Braftovi (encorafenib): assessment report. 2020. https://www.ema.europa.eu/en/documents/variation-report/braftovi-h-c-4280-ws-1695-epar-assessment-report-variation_en.pdf. Accessed 22 Feb 2021.
Array BioPharma Inc. BRAFTOVI® (encorafenib) capsules, for oral use: US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Accessed 22 Feb 2021.
Pierre Fabre Médicament. Braftovi (encorafenib): EU summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Accessed 22 Feb 2021.
Yaeger R, Yao Z, Hyman DM, et al. Mechanisms of acquired resistance to BRAF V600E inhibition in colon cancers converge on RAF dimerization and are sensitive to its inhibition. Cancer Res. 2017;77(23):6513–23.
Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–43.
Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) [abstract no. LBA32]. Ann Oncol. 2019;30(Suppl 5):v868.
Van Cutsem E, Huijberts S, Grothey A, et al. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol. 2019;37(17):1460–9.
Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273–84.
Kopetz S, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) [abstract no. 8]. J Clin Oncol. 2020;38(4 Suppl).
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer (version 4.2020). 2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 22 Feb 2021.
National Comprehensive Cancer Netword. NCCN clinical practice guidelines in oncology: rectal cancer (version 6.2020). 2020. https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed 22 Feb 2021.
National Institute for Health and Care Excellence. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. 2020. https://www.nice.org.uk/guidance/gid-ta10496/documents/final-appraisal-determination-document. Accessed 22 Feb 2021.
Acknowledgments
During the peer review process, the manufacturer of encorafenib was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
Zaina T. Al-Salama is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
The manuscript was reviewed by: K. Dimas, Department of Pharmacology, Faculty of Medicine, University of Thessaly, Larissa, Greece; G. Palma, Istituto Nazionale Tumori, IRCCS, “Fondazione G. Pascale”, Naples, Italy; J. Rogers, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; A. Zandi, Department of Pharmacology, Shahid Beheshti University of Medical Sciences School of Medicine, Tehran, Iran.
Rights and permissions
About this article
Cite this article
Al-Salama, Z.T. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation. Drugs 81, 849–856 (2021). https://doi.org/10.1007/s40265-021-01501-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-021-01501-5